UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/581,176	01/29/2007	Jerome Cassayre	70314/UST	1583
	7590 03/29/201 Protection, Inc.,	EXAMINER		
Patent and Trad	lemark Department	AULAKH, CHARANJIT		
	410 Swing Road Greensboro, NC 27409		ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			03/29/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/581,176	CASSAYRE ET AL.
Office Action Summary	Examiner	Art Unit
	Charanjit S. Aulakh	1625
The MAILING DATE of this communication a	ppears on the cover sheet with the	correspondence address
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perio Failure to reply within the set or extended period for reply will, by statu. Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be d will apply and will expire SIX (6) MONTHS froute, cause the application to become ABANDON	DN. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 29 This action is FINAL . 2b) ☑ The 3) ☐ Since this application is in condition for allow closed in accordance with the practice under	nis action is non-final. vance except for formal matters, p	
Disposition of Claims		
 4) Claim(s) 1-12 is/are pending in the application 4a) Of the above claim(s) is/are withdred 5) Claim(s) is/are allowed. 6) Claim(s) 11 and 12 is/are rejected. 7) Claim(s) 1-10 is/are objected to. 8) Claim(s) are subject to restriction and an are subject. 	rawn from consideration.	
Application Papers		
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) as a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examination is objected to by the Examination is objected.	ccepted or b) objected to by the deduction of the drawing of the d	tee 37 CFR 1.85(a). Objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in Applica iority documents have been recei au (PCT Rule 17.2(a)).	ation No ved in this National Stage
Attachment(s) 1) D Notice of References Cited (PTO-892)	4) 🔲 Interview Summa	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 8/2/06.	Paper No(s)/Mail 5) Notice of Informa 6) Other:	Date

Application/Control Number: 10/581,176 Page 2

Art Unit: 1625

DETAILED ACTION

1. According to paper filed on Jan. 29, 2010, the applicants have elected group I with traverse for further prosecution.

Response to Arguments

2. Applicant's arguments filed on Jan. 29, 2010 have been fully considered but they are not persuasive regarding restriction requirement. The examiner does not agree with the applicant's arguments on page 13 that a common core is present in various groups. It is not true. As stated clearly in the last office action, variables p, q and T are critical for the common core of these compounds. The examiner agrees with the applicants that in addition to compounds disclosed on pages 18-44 of the specification, the compounds I 2 to Ibo disclosed on pages 45-59 also fall within the elected group I. Thus, restriction requirement as indicated is proper and thereby made final.

3. Claims 1-12 are pending in the application.

Specification

4. This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1625

6. Claims 11 and 12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 11, the value of variable Y is not defined.

Claim 11 recites the limitation "H for the value of variable R8" in claim 10. There is insufficient antecedent basis for this limitation in the claim.

In claim 12, the applicants are suggested to insert a coma after insecticidal in line 1.

Claim Rejections - 35 USC § 102

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 7. Claim 12 is rejected under 35 U.S.C. 102(b) as being anticipated by Genin (Bioorg. & Medicin. Chem. Lett., cited on applicants form 1449).

Genin discloses spiro analog of HIV-1 reverse transcriptase inhibitor Ativerdine. The compound 1 disclosed on page 1877 by Genin anticipates the instant claim when Y is single bond, R1 is alkyl and R8 represents substituted alkyl group in the instant compounds of formula (I).

8. Claim 12 is rejected under 35 U.S.C. 102(b) as being anticipated by Gao (WO 00/27845, cited on applicants form 1449).

Gao discloses Spiro-indolines as Y5 receptor antagonists for treating obesity. The compounds 13-2 and 13-3 (see page 78) as well as compound in table VI where V represents N (see pages 29-30) disclosed by Gao anticipate the instant claim when variable R8 represents substituted alkyl group in the instant compounds of formula (I).

9. Claims 1-12 are objected for containing non-elected subject matter.

Application/Control Number: 10/581,176 Page 4

Art Unit: 1625

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit S. Aulakh whose telephone number is (571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571)272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Charanjit S. Aulakh/ Primary Examiner, Art Unit 1625